ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "tofacitinib and treatment"

  • Abstract Number: 2742 • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis

    Cristiano Zerbini1, Sebastiao Radominski2, Mario H. Cardiel3, Oswaldo Castañeda4, Ferope Romero5, Gustavo Citera6, Oscar Neira7, Dario Ponce de Leon8, Elaine Hoffman9 and Ricardo Rojo10, 1Centro Paulista de Investigação Clinica, São Paulo, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil, 3Centro de Investigacion Clinica de Morelia, Morelia, Mexico, 4Clínica Angloamericana, Lima, Peru, 5Hospital Arzobispo Loayza, Lima, Peru, 6Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 7Hospital del Salvador, Clínica Alemana, Santiago, Chile, 8Pfizer Inc, Lima, PA, Peru, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, New York, NY

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc pooled analysis was designed to assess the efficacy and safety…
  • Abstract Number: 459 • 2014 ACR/ARHP Annual Meeting

    Evaluation of the Effect of Tofacitinib on Measured Glomerular Filtration Rate in Patients with Active Rheumatoid Arthritis

    J. Kremer1, A.J. Kivitz2, J.a. Simon Campos3, E.L. Nasonov4, H. Tony5, B. Vlahos6, C. Hammond6, J. Bukowski6, H. Li6, S. Schulman6, S. Raber7, A. Zuckerman8 and J. Isaacs9, 1Albany Medical College and The Center for Rheumatology, Albany, NY, 2Altoona Center for Clinical Research, Duncansville, PA, 3Hospital CEM/BIOCEM, Merida, Mexico, 4Nasonova State Institute of Rheumatology, Moscow, Russia, 5University Hospital Würzburg, Würzburg, Germany, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, San Diego, CA, 8Pfizer Inc, Groton, CT, 9National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom

    Background/Purpose: In the clinical development program of the oral Janus kinase inhibitor tofacitinib for the treatment of rheumatoid arthritis (RA), small mean increases in serum…
  • Abstract Number: 458 • 2014 ACR/ARHP Annual Meeting

    Meta-Analysis of Serious Infections with Tofacitinib and Biological Treatment in Rheumatoid Arthritis Clinical Trials

    V. Strand1, S. Ahadieh2, J. French3, J. Geier4, S. Krishnaswami5, S. Menon5, T. Checchio2, R. Riese6 and J. Gomez-Reino7, 1Biopharmaceutical Consultant, Portola Valley, CA, 2Pharmacometrics, Pfizer Inc, Groton, CT, 3Metrum Research Group, Tariffville, CT, 4Pfizer Inc, New York, NY, 5Clinical Pharmacology, Pfizer Inc, Groton, CT, 6Pfizer Inc, Groton, CT, 7Hospital Clinico, Universitario de Santiago, Santiago, Spain

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Serious infection events (SIEs) have been reported in the tofacitinib…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology